What Is Semaglutide? GLP-1 Weight Loss Guide Nigeria

Understanding Semaglutide

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist -- a class of medication originally developed for type 2 diabetes management that has demonstrated remarkable efficacy for weight loss. It is a synthetic analogue of the naturally occurring human GLP-1 hormone, modified to have a significantly longer half-life in the body.

The active ingredient semaglutide is found in branded medications such as Ozempic^® (for diabetes) and Wegovy^® (for weight management), both manufactured by Novo Nordisk. Compounded versions containing the same active pharmaceutical ingredient are also available through licensed pharmacies with protocol guidance.

Key Facts at a Glance

Drug class: GLP-1 receptor agonist
Administration: Once-weekly subcutaneous injection
Primary uses: Weight management, type 2 diabetes
Active ingredient: Semaglutide (clinically studied molecule)

How Does Semaglutide Work?

Semaglutide works through three interconnected biological mechanisms that collectively produce significant, sustained weight loss.

01

Appetite Reduction

Semaglutide activates GLP-1 receptors in the hypothalamus, the brain's appetite control centre. This reduces hunger signals and food cravings, helping patients naturally consume fewer calories without the constant struggle of willpower-based dieting.

02

Delayed Gastric Emptying

The medication slows the rate at which food leaves the stomach and enters the small intestine. This prolongs feelings of fullness after eating, reducing the urge to snack between meals and naturally limiting portion sizes.

03

Blood Sugar Regulation

Semaglutide enhances glucose-dependent insulin secretion while suppressing glucagon release. This stabilises blood sugar levels, reducing energy crashes and the metabolic dysfunction that contributes to weight gain.

Who Is Semaglutide For?

Semaglutide for weight management is indicated for adults who meet specific clinical criteria. A qualified healthcare provider must evaluate each patient individually before prescribing.

Criteria	Details
BMI ≥ 30	Adults with obesity (no additional conditions required)
BMI ≥ 27	Adults who are overweight with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnoea)
Age	18 years and older (adolescent use requires specialist evaluation)
Prior Attempts	Patients who have not achieved adequate weight loss through diet and exercise alone

Important: Semaglutide is not appropriate for everyone. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC), those with Multiple Endocrine Neoplasia syndrome type 2 (MEN2), pregnant or breastfeeding women, and patients with a history of pancreatitis. Your doctor will conduct a thorough assessment before prescribing.

Available Forms

Semaglutide is available in two primary formulations, though the injectable form is significantly more commonly prescribed for weight management.

Subcutaneous Injection

Once-weekly self-administered injection
Thin needle into abdomen, thigh, or upper arm
Doses range from 0.25mg to 2.4mg
Primary form used for weight management
Higher bioavailability than oral form

Oral Tablet

Daily oral tablet taken on empty stomach
Must be taken with no more than 120ml of water
30-minute fasting period before eating
Primarily approved for type 2 diabetes
Lower bioavailability than injection

Semaglutide in Nigeria

The Nigerian market for GLP-1 weight loss therapies has grown significantly as awareness of these medications increases. Semaglutide is available in Nigeria through licensed providers offering compounded formulations under professional guidance.

Because Nigeria's tropical climate presents unique challenges for peptide medications, proper cold-chain storage and delivery are critical. Semaglutide must be stored between 2-8°C (36-46°F) and should never be frozen. Reputable providers maintain temperature-controlled logistics from dispensary to patient.

What to Look For in a Provider

Medical consultation before prescribing (not just order-and-ship)
Verified cold-chain delivery with temperature monitoring
Third-party lab testing certificates for purity and potency
Ongoing professional guidance and dosage titration support
Transparent pricing with no hidden fees

Clinical Evidence

Semaglutide has been extensively studied in large-scale clinical trials involving thousands of participants. Published peer-reviewed research demonstrates that GLP-1 receptor agonists like semaglutide produce clinically significant weight loss, with many patients achieving meaningful reductions in body weight over treatment periods of 68 weeks or longer.

Beyond weight loss, clinical literature has documented improvements in cardiometabolic risk factors including blood pressure, HbA1c levels, waist circumference, and lipid profiles. In 2024, semaglutide also received regulatory approval for reduction of cardiovascular events in adults with established cardiovascular disease and obesity or overweight.

References

Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes. Lancet. 2021;397(10278):971-984. PMID: 33667417
Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy. JAMA. 2021;325(14):1403-1413. PMID: 33625476
Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021;325(14):1414-1425. PMID: 33755728
Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131
Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. PMID: 29617641
Nauck MA, Meier JJ. Management of endocrine disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019;181(6):R211-R234. PMID: 31600725
Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity. Nat Med. 2022;28(10):2083-2091. PMID: 36216945
Blundell J, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight. Diabetes Obes Metab. 2017;19(9):1242-1251. PMID: 28266779
Knop FK, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity. Lancet. 2023;402(10403):705-719. PMID: 37385280

Medical Review

This article was reviewed by the Semaglutide.ng team for clinical accuracy. Content is based on published peer-reviewed research and is intended for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication.

Last reviewed: February 2026

What Is Semaglutide?